Biotechnology major Biocon on Saturday said the US health regulator has issued a complete response letter for Biocon Biologics' application for Insulin Aspart, a proposed biosimilar for diabetes treatment. The US Food and Drug Administration (USFDA) has issued a Complete Response Letter (CRL) to convey to the company that its initial review of an application is complete, and it cannot approve the application in its present form. "The CRL did not identify any outstanding scientific issues with the product. The CRL references the requirement for a satisfactory resolution of deficiencies from the pre-approval inspection (PAI) of our Malaysia facility for Insulin Aspart, held in August 2022," Biocon spokesperson said in a regulatory filing. The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022 that the agency found to be adequate and indicated that it would require a re-inspection of the Malaysia facility prior to the approval of the ..
from Latest News https://ift.tt/l7FIngf
via WebMD https://bsmedia.business-standard.com/_media/bs/img/article/2023-04/16/thumb/1681662285-2772.jpg
ABOUT THE AUTHOR
Hello We are OddThemes, Our name came from the fact that we are UNIQUE. We specialize in designing premium looking fully customizable highly responsive blogger templates. We at OddThemes do carry a philosophy that: Nothing Is Impossible
